Baseline and Early Treatment Response Variables Associated With Faricimab Durability in Treatment-Naive nAMD: TENAYA/LUCERNE Post Hoc Analyses

Related

• 

  VERONA: End-of-Study Results From a Phase 2 Trial of EYP-1901 (Vorolanib Intravitreal Insert) vs Afliberceptfor Diabetic Macular Edema

  Yasha S Modi, MD

  Annual Meeting Talks

  2025

• 

  Expert Panel: Faricimab and Aflibercept 8 mg in Diabetic Retinopathy

  Judy E. Kim, MD, FASRS

  Chirag D. Jhaveri, MD, FASRS

  Michael S. Ip, MD

  Arshad M. Khanani, MD, MA, FASRS

  Jordana G Fein, MD, MS

  Dennis M. Marcus, MD

  Diana V Do, MD, FASRS

  Annual Meeting Talks

  2024

• 

  Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials

  Arshad M. Khanani, MD, MA, FASRS

  Annual Meeting Talks

  2022